Locations:
December 1, 2018/Cancer/Research

Blinatumomab Trial: 66 Percent of Patients Achieve Remission from Acute Lymphoblastic Leukemia

Lower toxicity than conventional chemo

ALL_650x450

Remission rates of elderly patients with acute lymphoblastic leukemia (ALL) on a novel immunotherapy regimen appear to at least equal those observed with conventional chemotherapy — with less toxicity.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Results of the phase 2 trial of bispecific anti-CD19 antibody blinatumomab as induction and post-remission therapy were presented at the 2018 American Society of Hematology meeting in San Diego.

“Follow-up on the trial is still early, but the one-year estimated event-free and overall survival rates are encouraging,” says Anjali Advani, MD, Director of the Inpatient Leukemia Program at Cleveland Clinic Cancer Center. Dr. Advani was lead author of the study.

Immunotherapy-based regimens like this are likely to become the future standard of care for the elderly ALL population, which currently has a poor prognosis, she says.

The study

The antigen CD19 is expressed on most precursor B-cell ALLs. Previous studies have shown that the anti-CD19 antibody blinatumomab has been effective in relapsed/refractory ALL as well as minimal residual disease (MRD) ALL. That’s why Dr. Advani and a multicenter team through the National Clinical Trial Network evaluated the use of blinatumomab in patients (median age 75) with newly diagnosed Philadelphia chromosome negative B-lineage ALL.

Patients received blinatumomab for one to two cycles, until they attained a complete response (less than 5 percent marrow blasts with no evidence of extramedullary disease) with or without complete count recovery (absolute neutrophil count > 1000/uL, platelets > 100,000/uL). Once in remission, patients received three additional cycles of blinatumomab, followed by POMP (prednisone, vincristine, 6-mercaptopurine, methotrexate) therapy for 18 months.

Advertisement

Of the 29 patients treated, 19 (66 percent) had a complete response with or without complete count recovery. All but one of the 19 responded after only one cycle of blinatumomab. Of the 13 responders who had post-treatment MRD data, 12 (92 percent) achieved MRD negativity.

Kaplan Meier analysis estimates overall survival at six months to be 79 percent — 65 percent at one year. Disease-free survival at six months is estimated to be 68 percent — 56 percent at one year.

Hyperglycemia was the most common toxicity related to treatment, affecting four patients (14 percent). Toxicities affecting three patients (10 percent) were dyspnea, febrile neutropenia and hypertension. Two patients (7 percent) had lung infection.

There were no deaths in the first 28 days of the study treatment.

Next step: investigating drug combinations

“Novel therapeutic approaches are clearly needed for elderly patients with newly diagnosed ALL,” says Dr. Advani. “The outcomes of this treatment regimen appear promising.”

Longer follow-up is needed to determine duration of disease-free and overall survival.

Next steps will include investigating other treatments in combination with blinatumomab in the same population, notes Dr. Advani. One trial already in progress is studying the use of inotuzumab with blinatumomab.

Advertisement

Related Articles

Dr. Anwer and colleagues
November 12, 2026/Cancer/Blood Cancers

FDA Approval of Iberdomide Marks Historic Milestone in Multiple Myeloma

CELMoD therapy receives approval based primarily on measurable residual disease

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Ad